In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to...
Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of...
COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria...